Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3‑kinase/protein kinase B/glycogen synthase kinase 3β signaling pathway

Lu,Zhen; Xu,Aman; Yuan,Xiao; Chen,Kaiwei; Wang,Likun; Guo,Tao

doi:10.3892/ol.2018.8979

Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3‑kinase/protein kinase B/glycogen synthase kinase 3β signaling pathway

Authors:
- Zhen Lu
- Aman Xu
- Xiao Yuan
- Kaiwei Chen
- Likun Wang
- Tao Guo
View Affiliations

Affiliations: Department of General Surgery, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: June 18, 2018 https://doi.org/10.3892/ol.2018.8979
Pages: 3297-3302

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the anticancer effect of resibufogenin in gastric carcinoma cells through the phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT)/glycogen synthase kinase 3β (GSK3β) signaling pathway. MGC‑803 cells were treated with 0, 1, 2, 4 and 8 µM resibufogenin for 12, 24 and 48 h. Cell viability and apoptosis were measured using an MTT assay and annexin V staining. Caspase‑3 and caspase‑8 activity were identified using caspase‑3 and caspase‑8 activity kits and a variety of protein expression [B cell lymphoma (Bcl)‑2, Bcl‑2‑associated X protein (Bax), cyclin D1, cyclin E, PI3K, phosphorylated AKT, phosphorylated GSK3β and β‑catenin] were quantified using western blot analysis. It was revealed that resibufogenin effectively inhibited cell proliferation, and induced apoptosis and caspase‑3 and caspase‑8 activity in MGC‑803 cells. Furthermore, treatment with resibufogenin effectively increased Bax/Bcl‑2 expression, and suppressed cyclin D1, cyclin E, PI3K, phosphorylated AKT, phosphorylated GSK3β and β‑catenin protein expression in MGC‑803 cells. These results suggest that the anticancer effect of resibufogenin induces gastric carcinoma cell death through the PI3K/AKT/GSK3β signaling pathway, offering a novel view of the mechanism by which resibufogenin functions as an agent to treat gastric carcinoma.

View Figures

View References

1	Kawanaka M, Watari J, Kamiya N, Yamasaki T, Kondo T, Toyoshima F, Ikehara H, Tomita T, Oshima T, Fukui H, et al: Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: Analysis of molecular alterations by a randomised controlled trial. Br J Cancer. 114:21–29. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen J, Cheng L, Xie Z and Li Z: Impact of preoperative oral liquid carbohydrate on postoperative insulin resistance in gastric cancer patients and its associated study. Zhonghua Wei Chang Wai Ke Za Zhi. 18:1256–1260. 2015.(In Chinese). PubMed/NCBI
3	Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI and Jung KH: Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. Cancer Chemother Pharmacol. 72:953–964. 2013. View Article : Google Scholar : PubMed/NCBI
4	Li NA, Wang W, Xu B and Gong H: miR-196b regulates gastric cancer cell proliferation and invasion via PI3K/AKT/mTOR signaling pathway. Oncol Lett. 11:1745–1749. 2016. View Article : Google Scholar : PubMed/NCBI
5	Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Pan SY, Chen XW and Zhou SF: Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther. 9:1293–1318. 2015.PubMed/NCBI
6	Riquelme I, Tapia O, Espinoza JA, Leal P, Buchegger K, Sandoval A, Bizama C, Araya JC, Peek RM and Roa JC: The gene expression status of the PI3K/AKT/mTOR pathway in gastric cancer tissues and cell lines. Pathol Oncol Res. 22:797–805. 2016. View Article : Google Scholar : PubMed/NCBI
7	Zhang B, Yang Y, Shi X, Liao W, Chen M, Cheng AS, Yan H, Fang C, Zhang S, Xu G, et al: Proton pump inhibitor pantoprazole abrogates adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-β/β-catenin signaling and epithelial-mesenchymal transition. Cancer Lett. 356:704–712. 2015. View Article : Google Scholar : PubMed/NCBI
8	Guo H, Cui H, Peng X, Fang J, Zuo Z and Deng J, Wang X, Wu B, Chen K and Deng J: Modulation of the PI3K/Akt pathway and Bcl-2 family proteins involved in chicken's tubular apoptosis induced by nickel chloride (NiCl₂). Int J Mol Sci. 16:22989–23011. 2015. View Article : Google Scholar : PubMed/NCBI
9	Tang X, Zheng D, Hu P, Zeng Z, Li M, Tucker L, Monahan R, Resnick MB, Liu M and Ramratnam B: Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the β-Catenin/TCF/LEF-1 pathway in gastric cancer cells. Nucleic Acids Res. 42:2988–2998. 2014. View Article : Google Scholar : PubMed/NCBI
10	Chu Q, Xu H, Gao M, Guan X, Liu H, Deng S, Huo X, Liu K, Tian Y and Ma X: Liver-targeting Resibufogenin-loaded poly(lactic-co-glycolic acid)-D-α-tocopheryl polyethylene glycol 1000 succinate nanoparticles for liver cancer therapy. Int J Nanomedicine. 11:449–463. 2016.PubMed/NCBI
11	Xin XL, Sun JH, Wang XB, Xi RG, Wang G, Lan R, Su DH, Li H, Huo XK and Wang C: Microbial transformation of resibufogenin by Curvularia lunata AS 3.4381. J Asian Nat Prod Res. 16:290–295. 2014. View Article : Google Scholar : PubMed/NCBI
12	Mou LY, Xin XL, Chen L, Dong PP, Lan R, Su DH, Huang J, Wang JH and Zhan LB: Biotransformation of resibufogenin by Actinomucor elegans. J Asian Nat Prod Res. 16:623–628. 2014. View Article : Google Scholar : PubMed/NCBI
13	Liu J, Fu XQ, Zhou W, Yu HG, Yu JP and Luo HS: LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway. World J Gastroenterol. 17:181–190. 2011. View Article : Google Scholar : PubMed/NCBI
14	Xiao J, Chen Y, Li W, Gong J, Zhou Z, Deng Y, Wang L, Ren D, Wang J, Peng J and Lan P: Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: A phase II trial. Med Oncol. 32:3342015. View Article : Google Scholar : PubMed/NCBI
15	Shi D, Bao YS and Liu YP: Individualization of metal stents for management of gastric outlet obstruction caused by distal stomach cancer: A prospective study. Gastrointest Endosc. 78:277–284. 2013. View Article : Google Scholar : PubMed/NCBI
16	Ichikawa M, Sowa Y, Iizumi Y, Aono Y and Sakai T: Resibufogenin induces G1-phase arrest through the proteasomal degradation of cyclin D1 in human malignant tumor cells. PLoS One. 10:e01298512015. View Article : Google Scholar : PubMed/NCBI
17	Dolatkhah H, Movahedian A, Somi MH, Aghaei M, Samadi N, Mirza-Aghazade A and Esfahani A: Effect of PUFAs oral administration on the amount of apoptotic caspases enzymes in gastric cancer patients undergoing chemotherapy. Anticancer Agents Med Chem. 17:93–101. 2017.PubMed/NCBI
18	Frejlich E, Rudno-Rudzińska J, Janiszewski K, Salomon L, Kotulski K, Pelzer O, Grzebieniak Z, Tarnawa R and Kielan W: Caspases and their role in gastric cancer. Adv Clin Exp Med. 22:593–602. 2013.PubMed/NCBI
19	Su CC and Chiu TL: Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. Oncol Rep. 36:1173–1179. 2016. View Article : Google Scholar : PubMed/NCBI
20	Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P and Roa JC: The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 465:25–33. 2014. View Article : Google Scholar : PubMed/NCBI
21	Fu Z, Yang J, Wei Y and Li J: Effects of piceatannol and pterostilbene against β-amyloid-induced apoptosis on the PI3K/Akt/Bad signaling pathway in PC12 cells. Food Funct. 7:1014–1023. 2016. View Article : Google Scholar : PubMed/NCBI
22	Xing X, Zhang L, Wen X, Wang X, Cheng X, Du H, Hu Y, Li L, Dong B, Li Z and Ji J: PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs. 25:1129–1140. 2014. View Article : Google Scholar : PubMed/NCBI
23	Chen X, Liu Z, Cao BB, Qiu YH and Peng YP: TGF-β1 neuroprotection via inhibition of microglial activation in a rat model of parkinson's disease. J Neuroimmune Pharmacol. 12:433–446. 2017. View Article : Google Scholar : PubMed/NCBI
24	Kanninen KM and White AR: Type-I interferons in Parkinson's disease: Innate inflammatory response drives fate of neurons in model of degenerative brain disorder: An editorial comment on ‘Type-I interferons mediate the neuroinflammatory response and neurotoxicity induced by rotenone’. J Neurochem. 141:9–11. 2017. View Article : Google Scholar : PubMed/NCBI
25	Wang DL, Qi FH, Xu HL, Inagaki Y, Orihara Y, Sekimizu K, Kokudo N, Wang FS and Tang W: Apoptosis-inducing activity of compounds screened and characterized from cinobufacini by bioassay-guided isolation. Mol Med Rep. 3:717–722. 2010.PubMed/NCBI
26	Wang L, Yin J, Wang X, Shao M, Duan F, Wu W, Peng P, Jin J, Tang Y, Ruan Y, et al: C-type lectin-like receptor 2 suppresses AKT signaling and invasive activities of gastric cancer cells by blocking expression of phosphoinositide 3-kinase subunits. Gastroenterology. 150:1183–1195.e16. 2016. View Article : Google Scholar : PubMed/NCBI
27	Cho YJ, Kim JH, Yoon J, Cho SJ, Ko YS, Park JW, Lee HS, Lee HE, Kim WH and Lee BL: Constitutive activation of glycogen synthase kinase-3beta correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancer. BMC Gastroenterol. 10:912010. View Article : Google Scholar : PubMed/NCBI
28	Li Z, Cui J, Yu Q, Wu X, Pan A and Li L: Evaluation of CCND1 amplification and CyclinD1 expression: Diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers. Am J Transl Res. 8:142–153. 2016.PubMed/NCBI
29	Seiler R, Thalmann GN, Rotzer D, Perren A and Fleischmann A: CCND1/CyclinD1 status in metastasizing bladder cancer: A prognosticator and predictor of chemotherapeutic response. Mod Pathol. 27:87–95. 2014. View Article : Google Scholar : PubMed/NCBI
30	Neal JT, Peterson TS, Kent ML and Guillemin K: H. pylori virulence factor CagA increases intestinal cell proliferation by Wnt pathway activation in a transgenic zebrafish model. Dis Model Mech. 6:802–810. 2013. View Article : Google Scholar : PubMed/NCBI